VentiRx gets FDA fast track status for motolimod to treat ovarian cancer
Motolimod is indicated for ovarian cancer patients whose disease has progressed on or recurred after platinum-based chemotherapy. The new Toll-like receptor 8 (TLR8) immunotherapy, motolimid is currently being